Exhibit 107
Calculation of Filing Fee Tables
Form S-1
CinCor Pharma, Inc.
Table 1 – Newly Registered Securities
| Security Type | Security Class Title | Fee Calculation Rule | Amount Registered | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price(1)(2) | Fee Rate | Amount of Registration Fee | |||||||||
Fees to be Paid | Equity | Common stock, $0.00001 par value per share(3)(4) | 457(o) | — | — | $247,365,000 | .0000927 | $22,931 | ||||||||
Fees to be Paid | Equity | Pre-funded warrants to purchase common stock(4) | Other | — | — | — | — | — | ||||||||
Fees to be Paid | Equity | Common stock issuable upon exercise of pre-funded warrants(4) | 457(o) | — | — | — | — | — | ||||||||
Fees Previously Paid | — | — | — | — | — | — | — | — | ||||||||
| Total Offering Amounts | — | $247,365,000 | — | $22,931 | ||||||||||||
| Total Fees Previously Paid | — | — | — | — | ||||||||||||
| Total Fee Offsets | — | — | — | — | ||||||||||||
| Net Fee Due | — | — | — | $22,931 | ||||||||||||
| (1) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended, or the Securities Act. |
| (2) | Pursuant to Rule 416(a) under the Securities Act, this registration statement shall also cover an indeterminate number of additional securities that may from time to time be offered or issued to prevent dilution as a result of share splits, share dividends, dividends or other distributions, reclassifications, or similar transactions. |
| (3) | Includes shares of common stock that the underwriters have the option to purchase. |
| (4) | The proposed maximum aggregate offering price of the common stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the aggregate offering price of the pre-funded warrants offered and sold in the offering (plus the aggregate exercise price of the common stock issuable upon exercise of the pre-funded warrants), and as such the proposed aggregate maximum offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $247,365,000 (including the underwriters’ option to purchase additional shares of common stock). |
